MX379318B - Metodos para tratar trastornos de sueño de ritmo circadiano. - Google Patents

Metodos para tratar trastornos de sueño de ritmo circadiano.

Info

Publication number
MX379318B
MX379318B MX2018013663A MX2018013663A MX379318B MX 379318 B MX379318 B MX 379318B MX 2018013663 A MX2018013663 A MX 2018013663A MX 2018013663 A MX2018013663 A MX 2018013663A MX 379318 B MX379318 B MX 379318B
Authority
MX
Mexico
Prior art keywords
methods
sleep disorders
circadian rhythm
rhythm sleep
treating circadian
Prior art date
Application number
MX2018013663A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013663A (es
Inventor
Andrew Satlin
Carsten T Beuckmann
Margaret Moline
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2018013663A publication Critical patent/MX2018013663A/es
Publication of MX379318B publication Critical patent/MX379318B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2018013663A 2016-05-12 2017-05-11 Metodos para tratar trastornos de sueño de ritmo circadiano. MX379318B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662335599P 2016-05-12 2016-05-12
US201662335611P 2016-05-12 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US201662414599P 2016-10-28 2016-10-28
US201662414606P 2016-10-28 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (2)

Publication Number Publication Date
MX2018013663A MX2018013663A (es) 2019-07-18
MX379318B true MX379318B (es) 2025-03-10

Family

ID=58745465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013663A MX379318B (es) 2016-05-12 2017-05-11 Metodos para tratar trastornos de sueño de ritmo circadiano.

Country Status (16)

Country Link
US (2) US11096941B2 (cg-RX-API-DMAC7.html)
EP (2) EP3454859B1 (cg-RX-API-DMAC7.html)
JP (2) JP6888026B2 (cg-RX-API-DMAC7.html)
KR (2) KR102511855B1 (cg-RX-API-DMAC7.html)
CN (1) CN109640998A (cg-RX-API-DMAC7.html)
AU (3) AU2017264871B2 (cg-RX-API-DMAC7.html)
CA (1) CA3022068A1 (cg-RX-API-DMAC7.html)
ES (1) ES2904625T3 (cg-RX-API-DMAC7.html)
IL (2) IL291791B2 (cg-RX-API-DMAC7.html)
MX (1) MX379318B (cg-RX-API-DMAC7.html)
MY (1) MY199382A (cg-RX-API-DMAC7.html)
RU (1) RU2763493C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201809527UA (cg-RX-API-DMAC7.html)
TW (1) TWI795359B (cg-RX-API-DMAC7.html)
WO (1) WO2017197160A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807903B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809527UA (en) * 2016-05-12 2018-11-29 Eisai R&D Man Co Ltd Methods of treating circadian rhythm sleep disorders
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
MX2021016090A (es) * 2019-06-26 2022-02-03 Eisai R&D Man Co Ltd Lemborexant para el tratamiento de problemas del sueño.
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
CA3151634A1 (en) * 2019-09-13 2021-03-18 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating insomnia
US20240010629A1 (en) * 2019-12-11 2024-01-11 Teva Czech Industries S.R.O Solid state form of lemborexant
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
JP2024527024A (ja) * 2021-07-26 2024-07-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患に伴う不規則睡眠・覚醒リズム障害及び概日リズム睡眠障害を治療する方法における使用のためのレンボレキサント
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
KR20250070087A (ko) * 2022-09-23 2025-05-20 에자이 알앤드디 매니지먼트 가부시키가이샤 신경변성 질병과 관련된 신경변성의 감소 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06009377A (es) * 2004-02-20 2007-03-07 Lifescape Biosciences Inc Composiciones y metodos para regulacion del sueno.
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
MX2013003218A (es) 2010-09-22 2013-06-28 Eisai R&D Man Co Ltd Compuestos de ciclopropano.
CA2863413A1 (en) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
CN107810006B (zh) * 2014-10-23 2021-03-30 卫材R&D管理有限公司 用于治疗失眠的组合物
SG11201809527UA (en) * 2016-05-12 2018-11-29 Eisai R&D Man Co Ltd Methods of treating circadian rhythm sleep disorders

Also Published As

Publication number Publication date
EP3454859A1 (en) 2019-03-20
RU2763493C2 (ru) 2021-12-29
JP6888026B2 (ja) 2021-06-16
IL291791B2 (en) 2025-09-01
EP3454859B1 (en) 2021-12-01
IL291791B1 (en) 2025-05-01
US20200179382A1 (en) 2020-06-11
TWI795359B (zh) 2023-03-11
IL262803A (en) 2018-12-31
SG11201809527UA (en) 2018-11-29
IL291791A (en) 2022-06-01
AU2023203418A1 (en) 2023-06-29
MX2018013663A (es) 2019-07-18
ZA201807903B (en) 2021-04-28
ES2904625T3 (es) 2022-04-05
AU2017264871B2 (en) 2023-03-16
MY199382A (en) 2023-10-25
JP2021120410A (ja) 2021-08-19
WO2017197160A1 (en) 2017-11-16
IL262803B (en) 2022-05-01
JP2019518732A (ja) 2019-07-04
AU2017264871A1 (en) 2018-11-15
CN109640998A (zh) 2019-04-16
KR20190013820A (ko) 2019-02-11
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
RU2018143809A3 (cg-RX-API-DMAC7.html) 2020-09-17
KR102511855B1 (ko) 2023-03-20
CA3022068A1 (en) 2017-11-16
NZ748555A (en) 2025-06-27
RU2018143809A (ru) 2020-06-15
AU2025205336A1 (en) 2025-07-31
US20210353625A1 (en) 2021-11-18
US11096941B2 (en) 2021-08-24
JP7150096B2 (ja) 2022-10-07
BR112018073037A2 (pt) 2019-02-26
EP4056180A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
UY35464A (es) Inhibidores covalentes de kras g12c.
EA201790737A1 (ru) Комбинированная терапия
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
MX391720B (es) Terapia combinada para tratar cáncer.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX385425B (es) Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
DK3442513T3 (da) Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112017003644A2 (pt) métodos de tratamento de distúrbios do sono e para regular produção de melatonina.
BR112019002036A2 (pt) métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal
EP3402468C0 (en) PI3K P-DELTA 110 INHIBITORS FOR USE IN DELIVERY OF VIRUSES TO TREAT CANCER
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
PL3630112T3 (pl) Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu
HUE054910T2 (hu) Indazole vegyületek ín és/vagy ínszalag sérülés kezelésében történõ alkalmazásra
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).